Ernexa Therapeutics Inc. (ERNA): debt financing — Eterna Therapeutics issues $1.5M promissory note to Charles Cherington due Jan 8, 2024 at 6%

Ernexa Therapeutics Inc.

Principal amount $1,500,000; interest rate 6% per annum; matures January 8, 2024.
Promissory Note is a senior unsecured obligation; ranks equally with existing unsubordinated debt.
Proceeds received on December 8, 2023; use of proceeds not specified beyond general corporate purposes.
Customary events of default include payment failure, bankruptcy, material adverse effect.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Ernexa Therapeutics Inc. incurred loan of $1,500,000 with Charles Cherington at 6.0% per annum maturing January 8, 2024.

Instrument: loan
Principal: $1,500,000
Counterparty: Charles Cherington
Rate: 6.0% per annum
Maturity: January 8, 2024
Event: incurrence

Exact text from the filing

On December 8, 2023, Eterna Therapeutics Inc. (the “Company”) issued a 6.0% promissory note with an aggregate principal amount of $1,500,000 (the “Promissory Note”) to Charles Cherington.

View on SEC.gov

Browse all debt financings →

Ernexa Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-057648

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.